| Autor: |
Wijeratne T; Department of Neurology and University Department of Medicine, Melbourne Medical School, Sunshine Hospital, Western Health, St Albans, VIC 3021, Australia. Electronic address: tissa.wijeratne@wh.org.au., Bassetti CLA; Department of Neurology, University Hospital, Bern, Switzerland., Grisold W; Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Vienna, Austria., Dodick D; Mayo Clinic, Scottsdale, AZ, USA., Rouleau G; The Neuro (Montreal Neurological Institute-Hospital), Montreal, QC, Canada; Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada; Department of Neuroscience, McGill University Health Center, Montreal QC, Canada., Lewis SL; Lehigh Valley Health Network, Allentown, PA, USA., Stark R; Neurology Department, Alfred Hospital, Melbourne, VIC, Australia; Department of Neurosciences, Monash University, Melbourne, VIC, Australia., Freedman M; Division of Neurology, Baycrest Health Sciences, Toronto, ON, Canada; Division of Neurology (Medicine), University of Toronto, Toronto, ON, Canada., Guekht A; Moscow Research and Clinical Center for Neuropsychiatry, Moscow, Russia., Gouider R; Department of Neurology, Razi Hospital, University Tunis El Manar, Tunis, Tunisia., Medina MT; National Autonomous University of Honduras, Tegucigalpa, Honduras., Meshram C; Brain and Mind Institute, Nagpur, India., Basri H; Universiti Putra Malaysia, Kuala Lumpur, Federal Territory of Kuala Lumpur, Malaysia., Charway-Felli A; 37 Military Hospital, Accra, Ghana., Abdel Naseer M; Neurology Department, Cairo University, Cairo, Egypt. |
| Abstrakt: |
Competing Interests: The authors comprise the full World Federation of Neurology leadership team, trustees and regional leaders. DD reports receiving consulting fees from Amgen, Atria Health, Cerecin, Cooltech, Ctrl M, Allergan, Biohaven, GSK, Lundbeck, Eli Lilly, Novartis, Impel, Satsuma, Theranica, WL Gore, Nocira, Perfood, Praxis, AYYA Biosciences, and Revance; honoraria from Vector psychometric Group, Clinical Care Solutions, CME Outfitters, Curry Rockefeller Group, DeepBench, Global Access Meetings, KLJ Associates, Academy for Continued Healthcare Learning, Majallin, Medlogix Communications, MJH Lifesciences, Miller Medical Communications, WebMD Health/Medscape, Wolters Kluwer, Oxford University Press, and Cambridge University Press; research support from US Department of Defense, National Institutes of Health, Henry Jackson Foundation, Sperling Foundation, American Migraine Foundation, Patient Centered Outcomes Research Institute (PCORI); having stock options in Aural analytics, ExSano, Palion, Healint, Theranica, Second Opinion/Mobile Health, Epien, Nocira, King-Devick Technologies, Precon Health, AYYA Biosciences, and Atria Health; owning shares in Matterhorn and Ontologic; being on the board of directors for Epien, Matterhorn, Ontologics, King-Devick Technologies, and Precon Health; and having a non-royalty bearing patent (17189376.1-1466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis). SLL reports being acting secretary for the World Federation of Neurology (unpaid). RG reports a grant from Roche and receiving personal fees for participation on data safety monitoring board or advisrory board from Biogen, Hikma, Merck, Roche, and Sanofi. All other authors declare no competing interests. |
